Levetiracetam Mylan Generics

Levetiracetam, the active ingredient in Levetiracetam Mylan Generics, is an anticonvulsant presented as an oral dosage form for oral use. It is prescribed to manage various seizure types in patients with epilepsy, including partial‑onset, generalized tonic‑clonic and myoclonic seizures. It is used across adult and pediatric populations under medical supervision.

GNH USA supplies Levetiracetam Mylan Generics as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable global distribution for this essential antiepileptic medication.

Levetiracetam is an antiepileptic medication that modulates neuronal excitability to control seizure activity in the central nervous system. - Partial‑onset seizures: Decreases frequency and intensity of focal seizures in patients with epilepsy, improving quality of life. - Generalized tonic‑clonic seizures: Lowers the risk of convulsive episodes and improves overall seizure control, reducing hospitalizations. - Myoclonic seizures: Reduces sudden muscle jerks, aiding stability and daily functioning for affected individuals. - Adjunct therapy for refractory epilepsy: Provides additional seizure control when first‑line agents are insufficient.

Levetiracetam may cause a range of adverse reactions, varying from mild to serious. Common Side Effects: - Dizziness: Lightheadedness or unsteady feeling, especially when standing quickly. - Fatigue: Persistent tiredness that may affect daily activities. - Headache: Mild to moderate pain that can be intermittent. - Irritability: Mood changes such as increased agitation or short temper. - Nausea: Stomach discomfort or urge to vomit, often transient. Serious or Rare Side Effects: - Severe allergic reaction: Rash, swelling, or difficulty breathing requiring immediate medical attention. - Mood disorders: Depression, suicidal thoughts, or severe anxiety that may emerge during treatment. - Hematologic abnormalities: Low blood cell counts (e.g., leukopenia, thrombocytopenia) increasing infection or bleeding risk.

Before prescribing Levetiracetam, clinicians should consider several precautionary measures to ensure safe use. - Renal function: Adjust dose in patients with impaired kidney function. - Psychiatric history: Monitor for new or worsening depression, anxiety, or suicidal thoughts. - Pregnancy status: Evaluate risks and benefits, as safety data are limited. - Concomitant CNS depressants: Use caution when combined with other sedating agents. - Driving and machinery: Advise patients to assess personal response before operating vehicles or heavy equipment. - Store at ambient temperature: Keep below 25 °C in original packaging, protected from moisture.

Levetiracetam can interact with other medicines, altering its effectiveness or increasing adverse effects. Major Interactions (Avoid): - Carbamazepine: May significantly reduce levetiracetam plasma concentrations, potentially diminishing seizure control. - Phenobarbital: Can lower levetiracetam levels, increasing risk of breakthrough seizures. Moderate Interactions (Monitor Closely): - Alcohol: Concurrent use may enhance central nervous system depression, leading to increased drowsiness or dizziness. - Other antiepileptics (e.g., valproate, phenytoin): May require dose adjustments and therapeutic drug monitoring to maintain efficacy. - Oral contraceptives: Levetiracetam may slightly decrease hormonal contraceptive effectiveness; advise additional or alternative birth control methods.